Abstract
Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Keywords: CDC42, fibronectin, ML 141, MRSA, MSSA, pyrazolines, sepsis.
Current Pharmaceutical Biotechnology
Title:Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Volume: 15 Issue: 8
Author(s): Diana Cordero, Christopher R. Fullenkamp, Rachel R. Pelly, Katie M. Reed, Lindy M. Caffo, Ashley N. Zahrt, Micaleah Newman, Sarah Komanapalli, Evan M. Niemeier, Derron L. Bishop, Heather A. Bruns, Mark K. Haynes, Larry A. Sklar, Robert E. Sammelson and Susan A. McDowell
Affiliation:
Keywords: CDC42, fibronectin, ML 141, MRSA, MSSA, pyrazolines, sepsis.
Abstract: Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Export Options
About this article
Cite this article as:
Cordero Diana, Fullenkamp R. Christopher, Pelly R. Rachel, Reed M. Katie, Caffo M. Lindy, Zahrt N. Ashley, Newman Micaleah, Komanapalli Sarah, Niemeier M. Evan, Bishop L. Derron, Bruns A. Heather, Haynes K. Mark, Sklar A. Larry, Sammelson E. Robert and McDowell A. Susan, Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus, Current Pharmaceutical Biotechnology 2014; 15 (8) . https://dx.doi.org/10.2174/1389201015666140909124310
DOI https://dx.doi.org/10.2174/1389201015666140909124310 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention of Bioprosthetic Heart Valve Calcification: Strategies and Outcomes
Current Medicinal Chemistry Polyproline and Triple Helix Motifs in Host-Pathogen Recognition
Current Protein & Peptide Science The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews In Vitro and In Vivo Activities of Novel Cyclic Lipopeptides Against Staphylococcal Biofilms
Protein & Peptide Letters Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Anti-MRSA Cephems: An Update
Current Medicinal Chemistry - Anti-Infective Agents Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Quorum Sensing Inhibitors from the Sea: Lessons from Marine Symbiotic Relationships
Current Organic Chemistry Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Bacterial Protein Microarrays for Diagnosis of Infectious Diseases
Current Immunology Reviews (Discontinued) Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Current Topics in Medicinal Chemistry The Development of Antimicrobial Peptides as New Antibacterial Drugs
Current Protein & Peptide Science The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Drugs in Pediatric Ischemic Stroke
Current Drug Targets Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens
Current Respiratory Medicine Reviews